Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this study was to compare moclobemide and clomipramine in reactive depression according to the Newcastle II classification. Sixty patients were allocated to either 300 mg moclobemide, 150 mg clomipramine or placebo, all divided in 3 daily doses. Improvements occurred over time, but differences between treatments and compared with placebo were never statistically significant. Dizziness, tremor and anticholinergic symptoms were significantly more frequent with clomipramine than with moclobemide and placebo.
 ...
PMID:Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial. 266 41

Treatment with oestrogens in the perimenopause can regulate dysfunctional uterine bleeding and positively influence unpleasant subjective feelings such as sweating, dizziness, nervousness and lack or incapability of concentration. Oestrogens are especially successful in reactive depression and in the therapy of insomnia. Their positive effect on atrophic changes of the genitalia and in combating urge incontinence is also of therapeutic importance. Of particular socio-medical importance is their beneficial effect on postmenopausal osteoporosis. Side effects like weight gain, increase in blood pressure or changes in coagulation parameters are not observed during therapy with natural oestrogens in the usual doses. The incidence of thrombosis, embolism and myocardial infarction is not increased when oestrogens are given in the perimenopause. The controversy with respect to an increased incidence of endometrial carcinoma after long-term therapy with oestrogens may be based on an incorrect mode of administration as used on the Anglo-American scene. Excess dosage, continuous instead of intermittent therapy, lack of addition of progestational agents and a neglect of contraindications and risk factors may have led to the 3- to 8-fold increased incidence of endometrial carcinoma after oestrogen therapy in the studies from these areas.
 ...
PMID:[Advances and risks in estrogen therapy in the perimenopause]. 665 19

A 53-year-old woman with depressive symptoms and sleep problems, diagnosed as adjustment disorder with depressive reaction (ICD-10, F43.2), was treated with mirtazapine at a dose of 30 mg/day for a period of 10 weeks. In view of an imminent surgical intervention, the medication was than abruptly stopped. On the second day after discontinuation of mirtazapine, the patient developed a typical panic attack crisis with symptoms of palpitations, dyspnoea, retro-sternal pain, dizziness and nausea, blurred vision, anguish and fear of dying. During the next 5 days the patient suffered from severe, similar attacks recurring every 1-2 h, with each attack lasting about 20 min. Upon hospitalization and minor surgical intervention, the frequency and severity of symptoms regressed progressively, but the patient remained, with about one attack per week, not symptom free until the restitution of mirtazapine treatment at a dose of 30 mg/day. After re-introduction of mirtazapine panic attacks vanished, and during the entire follow-up period the patient remained symptom free. This case illustrates the risk of abrupt withdrawal of mirtazapine and indicates that, even after a medium-long therapy (10 weeks) with mirtazapine, progressive tapering-off of medication is advisable.
...
PMID:Recurrent, persisting panic attacks after sudden discontinuation of mirtazapine treatment: A case report. 2492 46